ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 38

Pre-Clinical Clonally-Expanded aggrecan89-103–Specific CD4+ T Cells Are a Target for Autoimmune Arthritis Prevention

Pascale Wehr1, Hendrik Nel1, Soi Cheng Law1, Diahann Jansen1, Nicole La Gruta2, Hugh Reid2, Jamie Rossjohn2 and Ranjeny Thomas1, 1University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Australia, 2Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Animal models, autoantibodies and rheumatoid arthritis, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Animal Models Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

In the pre-clinical rheumatoid arthritis (RA) prodrome, autoantibodies and transient symptoms may develop. Pre-clinical autoantibody development suggests concomitant expansion of autoantigen-specific CD4+ follicular helper T cells (TFH). A biased T cell receptor (TCR) repertoire in the joints of recent-onset RA patients suggests clonal expansion in early RA. Antigen-specific CD4+ T cells were clonally expanded at onset of murine collagen-induced arthritis. To model the pathogenetic role played by autoantigen-specific CD4+ T cells before and after autoantibody development, we longitudinally assessed the frequency, phenotype and clonotypic composition of the dominant aggrecan89-103 epitope-specific CD4+ T cell repertoire in proteoglycan-induced arthritis (PGIA). We aimed to elucidate how and when autoantigen-specific CD4+ T cells contribute to arthritis progression.

Methods:

PGIA was induced in BALB/cAnNCrl and BALB/c FoxP3-GFP mice by intraperitoneal injection (prime and two booster injections) of recombinant G1 epitope of human proteoglycan (rhG1-PG) emulsified in DDA adjuvant. MHC class II (IAd)-aggrecan89-103 tetramers and single-cell multiplex-nested PCR-TCR sequencing was used to study splenic aggrecan89-103-specific CD4+ T cells before and after onset of PGIA. Quantitative and phenotypic analysis of aggrecan89-103-specific CD4+ T cells was assessed by flow cytometry, based on the expression of CD44, CD62L, FoxP3, CXCR5 and PD1 and index sorting in TCR sequencing experiments. ELISA measured anti-human PG-specific antibodies.

Results:

Splenic aggrecan89-103-specific CD4+ T cells expanded in the prodrome before the detection of autoantibodies or persistent disease activity. Aggrecan89-103-specific CD4+ T cells shifted from naïve to activated effector memory (TEM) and TFH, associated with a loss of aggrecan­89-103-specific FoxP3+ Treg. CD4+ TCR β-chain variable genes (TRBV)13-1+, 13-2+ and 2+ aggrecan89-103-specific TEM and TFH cells clonally expanded in the prodromal period during transient joint inflammation. After clonotype depletion with anti-TRBV13 mAb, disease onset was delayed, autoantibody titres reduced and arthritis attenuated. Three public TRBV13+ clonotypes were shared between mice and between different BALB/c strains. All public clonotypes had conserved amino acid residues arising from convergent recombination, supporting selection of TCR for antigen recognition.

Conclusion:

Antigen-specific public clonotypes expand during the prodromal period, prior to development of autoantibodies. Therefore longitudinal antigen-specific TCR repertoire analysis prior to high titre autoantibody development may identify expanding autoreactive CD4+ T cell clones in individuals at risk of RA.


Disclosure: P. Wehr, None; H. Nel, None; S. C. Law, None; D. Jansen, None; N. La Gruta, None; H. Reid, None; J. Rossjohn, None; R. Thomas, None.

To cite this abstract in AMA style:

Wehr P, Nel H, Law SC, Jansen D, La Gruta N, Reid H, Rossjohn J, Thomas R. Pre-Clinical Clonally-Expanded aggrecan89-103–Specific CD4+ T Cells Are a Target for Autoimmune Arthritis Prevention [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/pre-clinical-clonally-expanded-aggrecan89-103-specific-cd4-t-cells-are-a-target-for-autoimmune-arthritis-prevention/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pre-clinical-clonally-expanded-aggrecan89-103-specific-cd4-t-cells-are-a-target-for-autoimmune-arthritis-prevention/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology